Similarities between Inherited Demyelinating Neuropathies and Wallerian Degeneration An Old Repair Program May Cause Myelin and Axon Perturbation under Nonlesion Conditions by Martini, Rudolf et al.
The American Journal of Pathology, Vol. 183, No. 3, September 2013ajp.amjpathol.orgMINI-REVIEW
Similarities between Inherited Demyelinating
Neuropathies and Wallerian Degeneration
An Old Repair Program May Cause Myelin and Axon
Perturbation under Nonlesion Conditions










martini@mail.uni-wuerzburg.de.opyright ª 2013 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2013.06.002Wallerian degeneration (WD) and inherited demyelinating neuropathies of the Charcot-Marie-Tooth
type 1 (CMT1) appear to represent completely distinct events. CMT1-like diseases are chronic disorders of
peripheral nerves that are genetically caused and lead to secondary neurodegenerative events, resulting
in usually non-treatable disabilities, whereas WD is an acute, usually transient, reaction on injuries,
aiming to allow peripheral nerve regeneration. Despite these differences, there are some striking simi-
larities regarding molecular characteristics of neural cells in the affected peripheral nerves. The most
conspicuous similarities might comprise the inﬂammatory component in both situations, as identiﬁed in
appropriate mouse models. However, although inﬂammation is a beneﬁcial component in WD, leading to
removal of regrowth-repellent myelin debris, inﬂammation in CMT1 mouse models causes damage of
initially intact nerve ﬁbers. We hypothesize that, in CMT1 models, molecular pathways are activated that
are shared with an important repair program after peripheral nerve injury, but lead to neural perturbation
when activated under nonlesion conditions, as is the case in CMT1. These novel insights into the path-
ogenesis of CMT1 might be instrumental for the development of new therapeutic options in humans.
(Am J Pathol 2013, 183: 655e660; http://dx.doi.org/10.1016/j.ajpath.2013.06.002)Supported by German Research Foundation grants Sonderforschungs-
bereich 581 and MA 1053/6-1, Charcot-Marie-Tooth Association (USA)
grant, Plexxikon Inc. (USA) grant, and University of Würzburg local funds
Interdisziplinäres Zentrum für Klinische Forschung A-122 (for projects of
the laboratory of R.M. related to this article).Inherited demyelinating neuropathies of the Charcot-
Marie-Tooth type 1 (CMT1) strongly reduce quality of life
because of typical neuropathological features, such as length-
dependent axonal degeneration, muscle atrophy, skeletal
deformities, and sensory dysfunctions. In the most common
forms of the CMT1 diseases, CMT1A, CMT1B, and
CMT1X, these uniform features are caused by gene muta-
tions related to distinct peripheral myelin-associated proteins,
such as peripheral myelin protein 22 (PMP22), myelin
protein zero (P0), or connexin 32 (Cx32),1 respectively,
suggesting some shared disease mechanisms with a similar
outcome. Studies in the corresponding mouse models iden-
tiﬁed components of the immune system as possible common
pathomechanistic pathways of the disorders.2e5 Based on
these studies, the question emerges why, under the genetic
disease conditions, a highly coordinated series of cellular and
molecular events occur that lead to nerve damage.stigative Pathology.
.The answer may be related to Wallerian degeneration
(WD), the reactive degeneration of axons and myelin of
nerves that experienced traumatic, adverse metabolic, toxic,
or other noxious conditions.6,7 In the peripheral nervous
system, this process occurs rather rapidly and is an important
prerequisite for successful axonal regeneration,8 possibly ex-
plaining the high evolutionary preservation of this process in
different species.9 One important feature that enables the rapid
speed of Wallerian degeneration is the inclusion of the innate
immune system, implicating a sophisticated cross talk between
lesioned axons, Schwann cells, and monocytic phagocytes that
remove nerve growtheattenuating components of the myelin
Martini et alsheaths.8,10 Interestingly, there is increasing evidence that, in
models for CMT1, inﬂammation by innate immune cells is
mediated by similar mechanisms as found in WD.4,10,11 Other
common immune-related features implicate intrinsic antibodies
that mark myelin for macrophage phagocytosis in WD and
potentially also in CMT1models (R.M. and D.K., unpublished
data).12Moreover, apart from the immune system,mediators of
Schwann cell dedifferentiation, such as c-Jun, appear to be
commonmolecular players of both WD and CMT1.13e16 Last,
molecular pathways that are involved in WD-related axon
degeneration7,17,18 have also been identiﬁed to participate in
axon loss in CMT models.
The present minireview will compare inherited peripheral
neuropathies of the CMT1 type with WD, with the aim to
analyze cellular and molecular similarities between both
processes affecting peripheral nerves as a result of primarily
different pathogenic events.Axon-Related Molecular Changes in Models for
Demyelinating Peripheral Neuropathies and WD
Although demyelinating forms of inherited neuropathies are
often caused by mutations in Schwann cell genes, a common
feature of these disorders is axonal perturbation, particularly
at distal aspects of long nerves.1,19e21 These axonal changes
are most important with regard to the clinical outcome of the
diseases. Although a trophic role of Schwann cells is like-
ly,21e23 it is not known why axons degenerate when the
Schwann cellerelated genes are mutated. The minimum
knowledge about the degenerative pathways of axons in
rodent models of demyelinating inherited neuropathies
concerns the partial molecular overlap with mechanisms
underlying WD.7,17,18 This process usually occurs as a result
of nerve injury and is an active process, rather than a passive
degenerative event of axons separated from their cell bodies,
as revealed by the analysis of the slow Wallerian degenera-
tion (WldS) mutant mouse.7 In this gain-of-function mutant,
axon stumps survive 10 times longer than normal after injury
because of neuronal overexpression of a chimeric fusion
protein.9 This fusion protein contains the NADþ biosynthetic
enzyme, nicotinamide mononucleotide adenylyltransferase
1 (Nmnat1), and 70 amino acids of Ube4b, an E4-type
ubiquitin ligase. A series of studies indicated that WldS
expression results in increased extranuclear Nmnat1, prob-
ably substituting for the protective activity of its isoform,
Nmnat2, which is quickly degraded after axonal injury, or
its mitochondrial isoform, Nmnat3.24 Recent observations
strongly suggest that WldS/Nmnat-mediated axonal protec-
tion results from stabilization of mitochondrial motility and
Ca2þ buffering capacity, thus preserving the physiological
functions of mitochondria, despite axonal injury.25
More important, the protective effect ofWldS is conserved
among different species and delays axonal degeneration in
noninjury models of distinct neurological disorders, in-
cluding peripheral neuropathies.7 As a ﬁrst contribution to656this topic, Samsam et al17 showed that axonal degeneration in
mice homozygously lacking P0 and mimicking CMT3 is
signiﬁcantly delayed when the mice are crossbred with WldS
mutants. Corresponding experiments with PMP22 over-
expressing rats mimicking CMT1A and transgenic WldS rats
revealed similar results.18 Another important mechanism
during WD is the implication of a recently identiﬁed prode-
generative axonal signaling program, comprising dSarm/
Sarm1.26 In analogy to studies with WldS mutants,17,18 it
remains to be determined if blockade of Sarm1 might atten-
uate axonal perturbation in peripheral neuropathies and other
disorders with axonal loss.
Schwann CelleRelated Molecular Changes in
Models for Demyelinating Peripheral
Neuropathies and WD
Inherited demyelinating neuropathies and WD have com-
mon molecular features regarding axonal degeneration and
concerning molecular alterations and dedifferentiating
phenotypes of the Schwann cells. For instance, Schwann
cells of models for inherited neuropathies express the same
cell surface molecules (eg, L1 and neural cell adhesion
molecule) as Schwann cells of lesioned nerves.27,28 Another
important molecule regarding Schwann cell phenotype is
the transcription factor component c-Jun.13 Parkinson et al14
identiﬁed this molecule as an antagonist of the promyeli-
nating transcription factor Krox-20 and as a dedifferentia-
tion- and demyelination-promoting molecule. In inherited
peripheral neuropathies29 and in the respective models,14
c-Jun is up-regulated, possibly keeping the Schwann
cells in a state of demyelination and low differentiation
phenotype. Regarding WD, it is most interesting that c-Jun
deﬁnes the phenotype of the so-called Büngner cells (ie,
Schwann cells sharing features of both Schwann cell
precursors and immature Schwann cells that enable axonal
regrowth).15
Inﬂammatory Pathways in Models for
Demyelinating Peripheral Neuropathies and WD
MEK/ERK Signaling and Cytokine Induction in Schwann
Cells and Fibroblasts
The generation of Büngner cells is dependent on c-Jun
activity and on elevated levels of phosphorylated extra-
cellular signaleregulated kinase (ERK), a downstream
intracellular signaling component of the Ras/Raf/mitogen-
activated protein/ERK kinase (MEK)/ERK pathway.30 To
enable stimulation of ERK signaling and investigate the
respective consequences related to Schwann cell dediffer-
entiation/Büngner cell formation, as they may similarly occur
under lesion conditions, mice that express the Raf kinase/
estrogen receptor fusion protein under the control of the
Schwann cellespeciﬁc P0 promoter have been generated.11ajp.amjpathol.org - The American Journal of Pathology
CMT1 and Wallerian DegenerationIn this way, activation of the ERK pathway induced
a dedifferentiated phenotype of Schwann cells and an
elevated expression of the inﬂammation-related cytokines,
monocyte chemoattractant protein (MCP)-1 (chemokine
ligand 2), macrophage inhibitory factor-1, IL-11, and
CXCL10.11 Moreover, an inﬂammatory response in the
form of an inﬂux of inﬂammatory cells partially reminiscent
of WD occurred, although expression levels of other cyto-
kines relevant in WD, such as IL-6 and tumor necrosis
factor-a, were either not elevated or have not been consid-
ered in the study, respectively.11
Although this study established that the MEK-ERK
signaling pathway is an important player in WD, it is not
clear how this pathway is initiated after injury. In a recent
study, Schwann cells have been identiﬁed to express the
neuregulin-1 isoform I (NRG1/I) as an important prerequi-
site for autocrine-mediated regenerative myelin formation
after WD.31 Proof of this concept was provided by gener-
ating Schwann cellespeciﬁc NRG1-null mice, which dis-
played a strongly reduced regenerative myelin formation.
As an interesting observation, the NRG1-deﬁcient Schwann
cells fail to show substantial ERK activation after nerve
injury,31 but the consequences for MCP-1 expression and
macrophage inﬂux/inﬂammation have not been addressed in
this study.
MEK-ERK activation has implications for WD, and for
CMT1 models, because activation of this pathway has been
identiﬁed as a typical feature of mutant Schwann cells in
three distinct forms of inherited peripheral neuropathies,
as exempliﬁed by mice heterozygously deﬁcient for P0
(CMT1B), hemizygously or homozygously deﬁcient for
Cx32 (CMT1X), or mildly overexpressing PMP22 (line C61;
CMT1A).3e5 Moreover, there is strong evidence that, in
these models, activation of the respective pathway leads to an
elevation of MCP-1, which is one of at least two important
components for macrophage recruitment and macrophage-
related demyelination in these models.10 The link between
MEK-ERK activation and MCP-1 expression has been
shown by systemically treating the CMT1 models or isolated
Schwannoma cells with the synthetic MEK inhibitor,
CI-1040, resulting in the expectedly lowered ERK phos-
phorylation and in an attenuated expression of MCP-1.3e5 In
one model, even macrophage inﬂux and some macrophage-
related pathological changes could be attenuated by MEK/
ERK inhibition, although systemic treatment was limited to
only 3 weeks.4 Thus, in models of CMT1 (ie, under condi-
tions initially distinct fromWD), the molecular axis of MEK/
ERK activationeMCP-1 expressionemacrophage activation
also occurs as in WD and appears to be crucially implicated
in the pathogenesis.3e5,10,11,32
By trying to combine the observations by Napoli et al11
and by Stassart et al31 and adapt them to potential mecha-
nisms in peripheral neuropathies, the following pathophys-
iological model could emerge: mutant Schwann cells might
lose communication with axons (possibly by hypothetical
ErbB2/3 dysregulation), resulting in increased NRG1/IThe American Journal of Pathology - ajp.amjpathol.orgexpression that leads to autocrine MEK-ERK phosphory-
lation. This will cause elevated downstream expression of
MCP-1 and activation of macrophages. Alternatively, it has
been speculated that in models for demyelinating inherited
neuropathies, MEK-ERK activation might be the result of
cellular stress, related to an unfolded protein response.10,33
In addition to MCP-1, colony-stimulating factor (CSF)-1
has been identiﬁed as another pathogenic player in distinct
models of CMT1.34,35 This was clearly demonstrated by the
observation that, in the CMT1 models, myelin and axons
were substantially and persistently preserved when CSF-1
expression was genetically inactivated, thus identifying
macrophages as myelin perturbators and not as innocent
scavengers or bystanders. Unexpectedly, this cytokine is not
a product of mutant Schwann cells but is expressed by
endoneurial ﬁbroblasts.35 It is presently not known which
signals let the ﬁbroblasts know about the genetic alteration
of the Schwann cells and induce them to secrete CSF-1.
According to our present observations, it is conceivable
that downstream products of the Schwann cellerelated
MEK-ERK pathway distinct from MCP-1 could serve as
a molecular bridge between Schwann cells and CSF-
1eproducing ﬁbroblasts.
Possible Roles of Antibodies
Considering the impact of macrophages in myelin phago-
cytosis in both inherited neuropathies and WD, the
question emerges how macrophages may recognize their
phagocytotic target. In 2010, Vargas et al12 showed that
endogenous antibodies accumulate rapidly after crush
injury at the distal myelin fragments. They also demon-
strated that mice lacking B lymphocytes (and, therefore,
incapable of producing antibodies) displayed delayed
macrophage recruitment and activation after nerve injury.
This resulted in reduced myelin clearance and slightly
compromised axonal regeneration, suggesting a signiﬁ-
cant role of endogenous antibodies in the course of
macrophage-related myelin removal and subsequent
axon regeneration.12 Interestingly, in models of CMT1,
a similar antibody accumulation can be detected, even in
the absence of mechanical nerve lesions. Moreover, by
investigating myelin-mutant mice lacking endogenous
antibodies, one model displayed reduced macrophage
activation, with attenuated phagocytic activity and atten-
uated deterioration of myelin integrity (R.M. and D.K.,
unpublished data). Our recent unpublished observations
are consistent with previous ﬁndings in recombination
activating gene-1edeﬁcient myelin mutants that dis-
played an amelioration of myelin degeneration in the
absence of mature T and B lymphocytes.36,37 It remains
to be proven if endogenous antibodies are involved in
myelin degeneration in some or most CMT1 models and
whether other serum components, such as comple-
ment,38,39 might also contribute to the primarily geneti-
cally caused myelin degeneration.657
Figure 1 Representative electronmicrographs of a ventral root of a CMT1
model (6-month-old Cx32-deﬁcient mouse; A) and of an injured plantar
mouse nerve (14 days after crush injury; B). Both in the CMT1 model and in
WD, myelin-laden macrophages (MF) are major cellular components at this
stage of active demyelination (A) and phagocytosis of myelin debris (B),
respectively. In both situations, macrophages are contacted by endoneurial
ﬁbroblasts (Fi; arrows). A: A demyelinated axon (ax) is associated with
a Schwann cell (sc) that likely lost myelin because of the active phagocytosis
of the macrophage. Other myelinated axons (Ax) and their myelinating
Schwann cells (Sc) appear (still) intact. B: Small regenerating axonal sprouts
(asterisks) are visible. Büngner cells (BCs), still devoid of regrowing axons,
are typical cellular components of the injured nerve after axons are degen-
erated. My, myelin ovoid. Scale bars: 2 mm (A and B).
Martini et alOpen Questions
It appears that in inherited demyelinating neuropathies,
secondary inﬂammatory mechanisms may occur, which areFigure 2 Synoptic view of cellular andmolecular interactions in models of demye
mutant Schwann cells show an activated ERK pathway (pERK) that leads to MCP-1 (che
the nerve. Hypothetically, ERK activation could be triggered by autocrine NRG1/I sec
CMT1 models, a postulated (but unknown) secreted molecule downstream of Schwan
have been shown to deliver CSF-1 to myelin-phagocytosing macrophages that directl
myelin of the mutant Schwann cells by the presence of decorating endogenous antib
which myelin ovoids are phagocytosed predominantly by immigrating macrophages. O
axon degeneration (Sarm1; Nmnat) and the up-regulation of glial dedifferentiation
a transcription factor component fostering demyelination and, in the case of WD, is ne
the WDmodel, axon damage (red ﬂash) is the primary cause for themolecular alteratio
a downstream result of the molecular alterations triggered by Schwann cellerelated
658normally activated under lesioning conditions. However, it
is presently not clear whether there is only partial or ex-
tended overlap between the genetic disorders and WD. For
instance, it remains to be shown which pathways mediate
the expression of the many other cytokines related to WD,
such as tumor necrosis factor-a, IL-1a, IL-1b, IL-6, IL-10,
and granulocyte-macrophage CSF,6,10,40,41 and whether
these may also have implications for inherited neuropathies.
For inherited neuropathies, it is also not yet known whether
M1 or M2 macrophage types are prevalent, as opposed to
WD, in which it is known that M2 macrophages appear to
be predominant.42 On the other hand, the pivotal role of
CSF-1 and its cellular source have been only identiﬁed in
CMT1 models,34,35,43 whereas its function in WD is not
well investigated.10 Moreover, neurotrophic factors appear
to be important in WD,6,40 but there is little knowledge
about their implications in inherited peripheral neuropathies.Conclusions and Future Perspectives
At ﬁrst glance, WD and CMT1-like disorders appear to
represent completely distinct events regarding cause, initi-
ation, progression, duration, and hypothetical therapeutic
interventions. While WD is an acute, usually transient, event
with inﬂammatory components, CMT1-like diseases are
viewed as chronic disorders that are genetically caused andlinating CMT neuropathy (left panel) and in WD (right panel). In CMT1models,
mokine ligand 2) expression that fosters macrophage (MF) transmigration into
retion, because it occurs in WD, in which it appears to cause ERK activation. In
n cellerelated ERK activation may activate endoneurial ﬁbroblasts (Fi), which
y or indirectly perturb axons (yellow ﬂash). These macrophages may recognize
odies (possibly recognizing myelin components), as has been proven in WD, in
ther mechanistic similarities between CMT1 and WD are pathways implicated in
markers, L1, neural cell adhesion molecule (NCAM), and c-Jun. The latter is
cessary for the generation of axon-regrowthepromoting Büngner cells (BCs). In
ns and phagocytosis, whereas in the CMT1model, axon damage (yellowﬂash) is
mutations and phagocytosis in the initial presence of noninjured axons.
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CMT1 and Wallerian Degenerationlead to secondary degenerative events, resulting in usually
non-treatable disabilities. For the ﬁrst scenario, the primary
research focus is on better/quicker axonal regeneration
and target ﬁnding8,44; basic interest in the latter is usually
on updating our knowledge with novel genetic data on
CMT1-like disorders, summarizing and categorizing clinical
issues, presenting hypotheses and models for the possible
pathogenetic pathways of gene mutations, and eventually
discussing possible biomarkers and hypothetical and past
therapeutic approaches.1,45e53 The present minireview tried
to bridge between both pathological conditions, identifying
remarkable similarities with possible therapeutic implica-
tions, particularly for the inherited disorders.
Regarding CMT1, clear similarities toWD are some neural
processes implicating axon-speciﬁc degeneration mecha-
nisms, but also glial-related changes, such as steps related to
Schwann cell dedifferentiation. According to our present
view, the most conspicuous similarity is the inﬂammatory
component in both events (Figure 1). Although inﬂammation
is viewed as a beneﬁcial event in WD, because of removal of
inhibitory myelin (thus, enabling axons to regrow substan-
tially),8 inﬂammation appears detrimental to myelin integrity
and axonal preservation in models for CMT1. Based on these
ﬁndings and considering the molecular similarities between
WD and CMT1 (Figure 2), it is plausible to assume that, in
the genetic disorders, some pathways related to the initially
beneﬁcial and, thus, evolutionary preserved mechanisms of
WD are ectopically and inappropriately activated. As an
adverse effect of this ectopic activation, the inﬂammatory
component appears to be deleterious to the initially non-
injured axons. It is conceivable that other forms of CMT
show cellular and molecular characteristics common to WD,
including inﬂammation. This is particularly expected for the
primarily axonal forms of inherited peripheral neuropathies
(CMT2), which, starting with axonal perturbations, might be
even closer related to WD than CMT1. However, corre-
sponding studies in animal models disclosing such similari-
ties are rare, so that future studies are necessary for a more
complete understanding of the respective disorders and their
possible relationship to WD.
Although in the CMT1 models discussed herein, the
detailed macrophage-related mechanisms that lead to
axon damage have not yet been elucidated, reducing this
macrophage-related inﬂammation might emerge as a thera-
peutic option for inherited demyelinating diseases.10,33,53
There are several hypothetical possibilities regarding how
this could be achieved. i) Because ERK activation is upstream
of the macrophage-activating chemokine, MCP-1, inhibitors
of this pathway (some of which are under clinical consider-
ation for malignancies54) might theoretically be an option.
However, the pleiotropic implication of the ERK pathway in
many cellular processes might be limiting regarding long-
term treatment of a chronic disorder. ii) Pharmacological
interventions of the CSF-1 pathway could be a promising
direction in attenuating macrophage-related myelin attack in
CMT1.55 iii) Systemic application of mesenchymal stemThe American Journal of Pathology - ajp.amjpathol.orgcells56e59 might be a third option. These cell types can
modulate the inﬂammatory milieu of the organism and
might, in this way, attenuate chronic inﬂammatory conditions
that occur in CMT1 neuropathies and other disorders of the
nervous system.Acknowledgments
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